Given the rarity of EGFR overexpression in the pathogenesis of CCA, further targeted therapy using small molecules or monoclonal antibodies should be evaluated in subsequent biomarker-stratified studies. The gene discussed is EGFR; the disease is cholangiocarcinoma.